

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 May 2009 (22.05.2009)

PCT

(10) International Publication Number
WO 2009/062898 A1

(51) International Patent Classification:
C07K 14/79 (2006.01) A61K 38/40 (2006.01)

(21) International Application Number:
PCT/EP2008/065186

(22) International Filing Date:
10 November 2008 (10.11.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07120713.8 14 November 2007 (14.11.2007) EP
60/990,066 26 November 2007 (26.11.2007) US

(71) Applicant (for all designated States except US): **Pharma-Surgics in Sweden AB** [—/SE]; Arvid Wallgrens Backe 20, S-413 46 Göteborg (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MATTSBY-BALTZER, Inger** [SE/SE]; Förtroligheten 23, S-412 70 Göteborg (SE). **DOLPHIN, Gunnar** [SE/FR]; 175 Allé du signal - les salinas, F-38480 Lепoint De Beauvoixin (FR).

(74) Agent: **AWAPATENT AB**; P.O. Box 11394, S-404 28 Göteborg (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau



WO 2009/062898 A1

(54) Title: NEW SYNTHETIC ARGININE SUBSTITUTED PEPTIDES AND THEIR USE

(57) Abstract: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.

NEW SYNTHETIC ARGININE SUBSTITUTED PEPTIDES AND THEIR USE

Field of the invention

The present invention relates to new peptides and to use thereof, in particular for
5 treatment and/or prevention of infections, inflammations and/or tumours.

Background art

Lactoferrin is a single chain metal-binding glycoprotein with a molecular weight of 77
kd. It has been found that the structural domain of lactoferrin responsible for the
10 bactericidal properties is a pepsin-cleaved fragment called lactoferricin (see e. g.
Bellamy W., et al., Identification of the bactericidal domain of lactoferrin, Biochim.
Biophys. Acta 1121: 130-136, 1992, and Bellamy W., et al., Antibacterial spectrum of
lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of
bovine lactoferrin, J. Appl. Bact. 73: 472-479, 1992).

15 Lactoferrin receptors are found on many types of cells including monocytes and
macrophages, lectin-stimulated human peripheral blood lymphocytes, brushborder
cells, and tumour cell lines.

Several patent publications describe the possible use of lactoferrin for treatment of
infections or inflammations. In WO 98/06425, e. g., it is disclosed that lactoferrin and
20 lactoferricin can be used for treatment and prevention of infections, inflammations and
tumours.

EP 629 347 describes an antimicrobial agent containing (A) lactoferrin hydrolysate
and/or one or more of antimicrobial peptides derived from lactoferrins, and (B) one or
more compounds selected from the group consisting of metal-chelating protein,
25 tocopherol, cyclodextrin, glycerine-fatty acid ester, alcohol, EDTA or a salt thereof,
ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a
salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof.
This antimicrobial agent is intended for treatment of products, and especially for safely
treating e. g. food and medicines. The agent according to this publication is thus a
30 new preservative. In the publication several peptide sequences are given and some of
them resemble the peptides according to the invention, although there are several
important differences described further below.

US 5,304,633 discloses antimicrobial peptides isolated from hydrolysates of human and bovine lactoferrin. Isolation of peptides corresponding to amino acids 12 to 47, and 17 to 41 of human lactoferrin are specifically disclosed.

5 JP 7145196 describes the preparation of antibiotic peptides by hydrolysis of lactoferrin. The preparation of a peptide corresponding to amino acids 17 to 41 of human lactoferrin is specifically described.

JP 8040925 discloses pharmaceutical compositions containing lactoferrin derived peptides and their use in the treatment of cornea damages, especially keratitis. Peptides corresponding to amino acids 17 to 41, 12 to 58, and 19 to 38, of human
10 lactoferrin are specifically disclosed

JP 7274970 describes the recombinant production of antibacterial lactoferricin derived peptides, specifically a peptides corresponding to amino acids 18 to 42 of human lactoferrin is disclosed.

JP 8143468 describes lactoferrin derived peptides and their use as antiulcer drugs, a
15 peptide corresponding to amino acids 19 to 33 of human lactoferrin is specifically disclosed.

WO 00/01730 describes peptides derived from human lactoferrin and their use for treatment of infections and inflammations.

EP 1 228 097 describes peptides derived from the immediate N-terminal end of
20 human lactoferrin and their use as microbial agents.

EP 1151009 describes peptides comprising a sequence corresponding to amino acids 35 to 50 of human lactoferrin having antimicrobial and/or endotoxin neutralizing activity.

WO 2006/047744 describes immunomodulatory peptides derived from the N-terminal
25 part of human lactoferrin comprising at least 33 amino acids and being substituted in both the N- and C-terminus with four positively charged amino acids.

Summary of the invention

The object of the present invention is to provide new synthetic peptides which can be
30 used for the same purposes as lactoferrin, lactoferricin or other lactoferrin derived peptides and which will have the same, or better, effects although having production, technical and/or biochemical advantages.

The aim of the studies leading to the present invention was to design new peptides which should essentially be as efficient as, or preferably more efficient, than human lactoferrin, human lactoferricin and other lactoferrin derived peptides in treatment and prevention of infections, inflammations, tumours, wounds, and scars.

- 5 It was found that peptides formed of the sequences constituted of all or some of the amino acids 21-31 of human lactoferrin counted from the N-terminal end, further substituted with arginine containing peptides, have the desired properties.

According to the present invention, it is shown that the peptides designed based on the sequence constituted of amino acids 21-31 from the N-terminal end of human
10 lactoferrin, substituted with arginine containing peptides, have the desired properties.

It has been shown that humans in their brush border membrane have receptors which can bind to human lactoferrin (see e. g. Lonnerdal B., Lactoferrin receptors in intestinal brush border membranes, Adv. Exp. Med. Biol. 1994, 357: 171-175). It has also been shown that bovine lactoferrin does not bind to these receptors. A plausible
15 mechanism for the uptake of these new peptides in the human body is that the peptides are taken up through binding to cellular receptors. However, the invention is in no way limited to this mechanism.

Thus, the present invention relates to new synthetic peptides and to functionally equivalent homologues or analogues thereof.

- 20 Furthermore, the invention relates to medicinal products and to food stuff, especially infant formula food, comprising said peptides.

The invention also relates to use of said peptides for the production of medicinal products for treatment and prevention of infections, inflammations and tumours.

- The peptides according to the invention are fungicidal and bactericidal, and can thus
25 be used for other applications when substances with such properties are desired.

They may for example be used as preservatives.

The characterising features of the invention will be evident from the following description and the appended claims.

- 30 Detailed description of the invention

Thus, the present invention relates to peptides designed based on the amino acid sequence of fragments of the protein human lactoferrin (hLF). The fragment of hLF

when X8 is Glu or Asp then R3 is Ser-(Arg)_n-X9 and the bond α is an amide bond between the γ -carboxyl group of Glu or the β -carboxyl group of Asp and the amino group of Ser;

amino acid X9 is either no amino acid or Gly;

- 5 and n is an integer from 1 to 10, preferably an integer from 2 to 6, preferably an integer from 4 to 6, or even more preferably an integer from 3 to 4;

R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 3 and N-terminally truncated fragments thereof including

- 10 Gly-Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 15 Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 20 Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Pro-Glu-Ala-Thr-Lys-Cys,
 Glu-Ala-Thr-Lys-Cys,
 25 Ala-Thr-Lys-Cys,
 Thr-Lys-Cys,
 and
 Lys-Cys,

- 30 Preferably R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 11 and N-terminally truncated fragments thereof including

Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,

5 Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Pro-Glu-Ala-Thr-Lys-Cys,
 Glu-Ala-Thr-Lys-Cys,
 Ala-Thr-Lys-Cys,
 Thr-Lys-Cys,
 10 and
 Lys-Cys,

R2 is either no amino acid, Pro or a peptide sequence selected from SEQ ID NO:4
 and C-terminally truncated fragments thereof including
 Pro-Pro-Val-Ser-Cys-Ile-Lys-Arg,

15 Pro-Pro-Val-Ser-Cys-Ile-Lys,
 Pro-Pro-Val-Ser-Cys-Ile,
 Pro-Pro-Val-Ser-Cys,
 Pro-Pro-Val-Ser,
 Pro-Pro-Val, and
 20 Pro-Pro;

The above peptide sequences defining R2 thereby being represented by SEQ ID NO:
 4 or C-terminally truncated fragments thereof.

In one preferred embodiment X8 is Gly and R3 is Ser-(Arg)_n-X9 and the bond α is a
 peptide bond between the carboxyl group of Gly and the amino group of Ser.

25 In another preferred embodiment X8 is Lys and R3 is X9-(Arg)_n-Ser and the bond α is
 an amide bond between the ϵ -amino group in Lys and the carboxyl group in Ser.


In another preferred embodiment X8 is Glu and R3 is Ser-(Arg)_n-X9 and the bond α is
 an amide bond between the γ -carboxyl group of Glu and the amino group of Ser.

In other preferred embodiments amino acid X1 is Gln, X2 is Trp, X3 is Gln or Lys, X4
 30 is Arg, X5 is Asn or Ala, X6 is Met, and/or X7 is Arg.

In another preferred embodiment R1 is either no amino acid or the peptide sequence
 Ala-Thr-Lys-Cys.



- Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg
 |
 Gly-Arg-Arg-Arg-Arg-Ser;
 5
- Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg
 |
 Gly-Arg-Arg-Arg-Arg-Ser;
- 10 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH₂
 |
 Gly-Arg-Arg-Arg-Arg-Ser;
- 15 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg
 |
 Gly-Arg-Arg-Arg-Arg-Ser;
- 20 Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg
 |
 Gly-Arg-Arg-Arg-Arg-Ser;
- 25 Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg-NH₂
 |
 Ac-Gly-Arg-Arg-Arg-Arg-Arg-Ser
- 30 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH₂
 |
 Gly-Arg-Arg-Arg-Arg-Ser;
- 35 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg
 |
 Ser-Arg-Arg-Arg-Arg-Gly-NH₂;
- 40 Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg
 |
 Ser-Arg-Arg-Arg-Arg-Gly-NH₂;



Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Gly-NH₂;
(SEQ ID NO: 10)

CysM is acetamidomethyl-cysteine.

- 5 Where the N-terminally and/or C-terminally capped form of a peptide has been given, it is also possible, according to the invention, to use the un-capped forms.

Where the N-terminally and/or C-terminally un-capped form of a peptide has been given, it is also possible, according to the invention, to use the capped forms.

- 10 The sequences Gly-Arg-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Ser, Ser-Arg-Arg-Arg-Arg-Arg-Gly, Ser-Arg-Arg-Arg-Arg-Gly and Ser-Arg-Arg-Arg-Gly are positively charged under physiological conditions and are capable of strong and specific interactions with receptors. They are therefore an important part of the peptides according to the invention.

- 15 The advantage of the peptides according to the invention is that they comprise the part of the lactoferricin fragment of the human lactoferrin protein, or a modified version thereof, which the inventors have found to be active with regards to the invention.

- 20 In some cases only the capped form of a sequence has been given in the appended sequence listing. However, it is also possible, according to the invention, to use the non-capped forms.

Further substitution of active fragments of hLF with an Arg containing peptide resulting in the peptides of the present invention has been shown to provide peptides with improved properties compared to other known peptides derived from hLF.

- 25 The peptides according to the invention are suitable for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars. The term "treatment" used herein refers to curing, reversing, attenuating, alleviating, minimising, suppressing or halting the deleterious effects of a disease state, disease progression or other abnormal condition, and the term "prevention" used herein refers to minimising, reducing or suppressing the risk of developing a disease state or
30 progression or other abnormal or deleterious conditions.

The infections treatable with the peptides or medicinal products according to the invention include infections caused by all kinds of pathogens, such as bacteria, viruses, fungi, etc.

It is also possible to treat different types of inflammations. Inflammation is a complex phenomenon marked i.a. by abnormal "redness" and swelling of tissues and organs, pain and heat in affected areas, capillary dilation, leucocyte infiltration, etc.

5 Inflammation is primarily caused by exposure to bacterial and other noxious agents and physical injury. Inflammation has many forms and is mediated by a variety of different cytokines and other chemical signals. These mediators of inflammation include tumour necrosis factor- α (TNF- α), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and various colony-stimulating factors (CSFs).

10 As stated above, the peptides according to the invention are also suitable for treatment of tumours.

The peptides according to the invention may either be used as they are or be included in a medicinal product or a pharmaceutical preparation. The medicinal product or a pharmaceutical preparation according to the invention may also comprise substances used to facilitate the production of the pharmaceutical preparation or the
15 administration of the preparations. Such substances are well known to people skilled in the art and may for example be pharmaceutically acceptable adjuvants, carriers and preservatives.

The peptides according to the invention may either be formulated for oral administration, systemic administration, parenteral administration, local administration
20 or topical administration.

The peptides or medicinal products according to the invention can be administered to a patient either orally, systemically, parenterally, locally or topically. The term "patient" used herein relates to any person at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition.

25 The systemic administration is suitable e. g. for treatment of urinary tract infection, colitis and tumours. The systemic administration can be undertaken by oral, nasal, intravenous, intraartery, intracavitary, intramuscular, subcutaneous, transdermal, suppositories (including rectal) or other routes known to those of skill in the art. Oral administration is preferred.

30 The local administration is suitable e. g. for treatment of skin infections, all infections and inflammations in mucosal membranes etc. The local administration can be undertaken by topical, oral, nasal, vaginal or oropharyngeal route. For treatment of local infections or inflammations in the skin or mucosal membranes the peptides or

medicinal products according to the invention may e. g. be included in a gel, a cream, an ointment, or a paste.

In the method according to the invention an effective amount of a peptide according to the invention is administered to a patient. The term "effective amount" used herein
5 relates to an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious conditions.

The peptides or medicinal products and methods according to the invention are particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable
10 according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by fungi, e.g. Candida species such as Candida albicans and Candida krusei, Aspergillus and Cryptococcus neoformans. This listing is in no way limiting the scope of the invention.

15 The peptides, medicinal products and methods according to the invention are also well suited for preventive medical care by reducing the risk of developing urinary tract infection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications.

The peptides of the present invention are suited for are anti-inflammatory and
20 immunomodulatory therapies, exemplified but not limited to:

- 1) Generally, treatment of inflammation and/or medical condition resulting from inflammation, and specifically,
 - 2a) Intestine; Morbus Crohn, Colitis, Ulcerative colitis,
 - 2b) Joints; Rheumatoid arthritis, Arthritis, Arthrosis, Localized disorders of muscles
25 including muscle spasm, muscle tear, muscle injury, muscle strain, muscle sprain,
 - 2c) Dermatology; Psoriasis, Eczema (excema), Dermatitis, Acne
 - 2d) Heart; Pericarditis, Endocarditis Cardiac insufficiency,
 - 2e) Pain; (further specified under 2f below).
 - 2f) Nervous system; Alzheimer, Multiple Sclerosis, Carpal tunnel syndrome, Disc
30 herniation, Cervical rhizopathy, Bells palsy, Acute spinal cord injury, Spinal cord compression, Spinal stenosis, Postherpetic neuralgia, Viral encephalitis, Viral meningitis, Menieres disease, Polio and postpolio complications, Chronic Inflammatory Demyelinating Polyneuropathy, Polyneuropathy, Trigeminal neuralgia, Chronic epileptic disorders,

- 2g) Sensory organs; Glaucoma
 2h) Mucosal surfaces (inflammation as a result of chemo/radiation therapy),
 2i) Allergy,
 2j) Autoimmune diseases
- 5 The peptides of the invention are further suited for prevention and treatment of wounds and scars in connection with conditions and procedure, exemplified but not limited to:
- 3a) surgical procedures on various tissues such as skin, muscles, tendons, nervous tissue, blood vessels, and at different locations of the body such as eyes, ears, vocal
 10 cord, hand, spinal cord, intra-abdominal cavity, intra-thoracic cavity, intra-cranial cavity, oral cavity, gynecological procedures, endometriosis, phimosis,
 3b) acne
 3c) hypertrophic scars & keloids,
 3d) pleuritis,
 15 3e) peritoneal dialysis,
- The peptides of the invention are further believed to have anti-angiogenic effects and are therefore suited for treatment of :
- 4a) Cancer
 4b) Rheumatoid arthritis
- 20 The peptides of the invention have anti-infectious effects, and are suited for the prevention and treatment of:
- 5a) Antibacterial effects:
 Upper and lower respiratory tract (tonsillitis, sinusitis etc.)
 Infections of the eye (e.g. conjunctivitis)
 25 Urinary tract infections
 Sexually transmitted diseases (including antimicrobial coating of condoms)
 Genital tract including vaginosis, vaginitis, cervicitis, endometritis, PID
 Gastrointestinal tract infections (systemic infections initiated in the GI)
 Central nervous system infections
- 30 Infections of the skin (including staphylococci, for instance MRSA, nosocomial, wounds, burns), muscle, joints (e.g. septic arthritis), bone and hemopoietic system
 Infections related to the mouth, including parodontitis, gingivitis
- 5b) Antiviral effects:
 Upper and lower respiratory tract
 35 Sexually transmitted diseases

Gastrointestinal tract infections (systemic infections initiated in the GI)

Central nervous system infections

5c) Antifungal effects:

Upper and lower respiratory tract (such as aphthae, mucocutaneous candidiasis)

5 Genitourinary tract, such as vulvovaginal candidiasis, balanitis,

Gastrointestinal tract infections (systemic infections initiated in the GI)

Central nervous system infections

Infections of the skin (such as mucocutaneous candidiasis)

10 The peptides, medicinal products and methods according to the invention may either be used alone, in combination with each other or in combination with conventional therapy.

15 According to the present invention it is also possible to include the peptides, in an effective amount, in any kind of food or beverage intended to reduce infections and/or inflammations in patients running an increased risk of such conditions due to an underlying disease, a low birth weight or a medical treatment. For example, it is possible to include the peptides, in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants. When the peptides according to the invention is to be used in food stuffs, e. g. for nutritional purposes, it is especially preferred to use peptides of natural origin.

20 Since the peptides according to the invention have antimicrobial effects they can also be used as preservatives in different food stuffs and medicinal products such as gels, creams, ointments, pastes, solutions, emulsions etc.

25 The invention will now be further explained in the following examples. These examples are only intended to illustrate the invention and should in no way be considered to limit the scope of the invention.

Brief description of the drawings

30 Figure 1. Growth inhibition of *E.coli* in the presence of HLB Darg1 and a 23-a.a. long peptide (amino acids 18 to 40 of hLF). Using a peptone medium (1%) the microplate was incubated over night and read spectrophotometrically at 650 nm. As can be seen a concentration of 12.5 µg/ml totally reduced the growth.

Figure 2. A) The number of *S.aureus* located in the joints of peptide-treated and vehicle treated animals. B) The distribution of animals with a scoring of 3 or more (the most severe inflammation and/or erosion of joint tissue was scored as 5, and no histological changes as 0). A dose of 2×10^4 *S.aureus* and 100 μg of peptide (HLBDarg1) were injected.

Figure 3. Effects of peptide treatment in *Candida* skin infection (quadruple spots for each peptide). The treatment dose was 400 μg per infected area. The arginine containing peptide reduced *C.albicans* to a higher degree than a longer peptide sequence based on the antimicrobial region in LF (peptide 25 a.a. = peptide corresponding to amino acids 16-40 of hLF).

Figure 4. Inhibitory activity of a lactoferrin-derived (HLBD1 Arg rak) peptide on IL-1-induced IL-6 (A) or PAI-1 (B) production in MeT-5A cells. Indicated peptide concentrations were added to cells in triplicate ($n=3$) immediately after the addition of IL-1, the cell supernatants were collected after 3 hours (in A) or 6 hours (in B) of incubation and analyzed for IL-6 (in A) or PAI-1 (in B) by quantitative ELISA. The results are expressed in relation to the IL-6 level (288 pg/ml) or PAI-1 level (18.3 ng/ml) obtained without any peptide added, respectively. Statistical differences were determined by two-sided Student's t-test (* $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.005$; **** $p \leq 0.001$).

Figure 5. Dose-inhibitory activity of a lactoferrin-derived peptide (HLBD1 Arg rak) on LPS-induced TNF- α secretion in human monocyte derived macrophage cell line THP-1 cells. Indicated peptide concentrations were added to cells in triplicate ($n=3$) 30 min after the addition of LPS (0.1 ng/ml). TNF- α levels at 6 h after the stimulation were measured by ELISA (R&D Systems, Minneapolis, MN). The results are expressed in relation to TNF- α levels (290 pg/ml) obtained without any peptide added. Statistical differences among genotypes were determined by two-sided Student's t-test (* $p \leq 0.05$).

Figure 6. Dose-inhibitory activity of lactoferrin-derived peptides on IL-1 β -induced IL-6 (A) or PAI-1 (B) production in MeT-5A cells. Indicated peptide concentrations were

added to cell in triplicate (n=3) immediately after the addition of IL-1 β , the cell supernatants were collected after 3 hours (in A) or 6 hours (in B) of incubation and analyzed for IL-6 (in A) or PAI-1 (in B) by quantitative ELISA. The results are expressed in relation to the IL-6 level (1770 pg/ml) or PAI-1 level (63.0 ng/ml) obtained without any peptide added. Statistical differences were determined by two-sided Student's t-test (* p \leq 0.05;). \blacklozenge = HLBDarg1rak, \blacktriangle = PXL11, \blacktimes = PXL12, \blacksquare = PXL13, \bullet = PXL14.

Figure 7. Dose-inhibitory activity of of lactoferrin-derived peptides on LPS-induced TNF- α secretion in human monocyte derived macrophage cell line THP-1 cells. Indicated peptide concentrations were added to cells in triplicate (n=3) 30 min after the addition of LPS (0.1 ng/ml). TNF- α levels at 6 h after the stimulation were measured by ELISA (R&D Systems). The results are expressed in relation to TNF- α levels (273-775 pg/ml) obtained with peptide added at 10 μ g/ml. Statistical differences were determined by two-sided Student's t-test (* p \leq 0.05;). \blacklozenge = HLBDarg1rak, \blacktriangle = PXL11, \blacktimes = PXL12, \blacksquare = PXL13, \bullet = PXL14.

Examples

Example 1. Antimicrobial assay

Arg-Arg-Arg-Arg- or Arg-Arg-Arg- containing peptides (Table 1) have been analysed
5 by an antimicrobial assay using *E.coli*, *S.aureus* and *C.albicans* as test
microorganisms.

Washed cells were suspended in 1% Bactopeptone (BP)(Difco, USA). The
concentration of bacterial or fungal cells was spectrophotometrically adjusted.
Peptides serially diluted in BP by twofold steps were added in duplicate or triplicate to
10 the wells of a microtiterplate (200 μ l per well). The bacterial or yeast cell solutions
were added in 10 μ l volumes to give a final concentration of approximately 2×10^5
cells per ml. The concentration of the stock solution was always checked by viable
counts. The microplate was incubated at 37°C in a humid chamber for 2 h unless
otherwise stated. Five μ l were taken from each well and added as a drop onto a blood
15 agar plate and incubated over night at 37°C.

The concentration of lactoferrin or peptide causing a 99% reduction of the inoculum
was defined as the MMC₉₉.

The microbicidal activity of the peptides showed that all peptides were better than the
20 natural sequence amino acids 1-31 (HLBD31) except for HLBDarg2 (Table 2). In this
peptide the Arg-Arg-Arg-Arg-Arg sequence was linked to phenylalanine from the
amino-terminal side via a spacer (three glycine residues).

In Figure 1 the growth inhibition of HLBDarg1 was compared with a native lactoferrin-
derived peptide HLBD2 consisting of amino acids 18 to 40. A much stronger
25 antimicrobial activity was recorded for HLBDarg1 in this medium which strongly
reduces the antimicrobial activity of many other LF derived peptides.

Table 1. Arginine-tailed peptides used in the Examples

Peptide	Sequence
HLBD Arg1	Ac- F Q W Q R N M R K V R K -NH ₂ G R R R R S
HLBD Arg1 rak	Ac- F Q W Q R N M R K V R G S R R R R G -NH ₂
HLBD Arg2	G R R R S G G F Q W Q R N M R K V R
HLBD Arg5	Ac- F Q W Q R N M R K V R K -NH ₂ G R R R S
HLBD Arg1optC	Ac- F Q W Q R A M R K V R K -NH ₂ G R R R S
HLBD Arg1optC(K24)	Ac- F Q W K R A M R K V R K -NH ₂ G R R R S
HLBD2 optC Arg1	A T K Cm F Q W Q R A M R K V R K P P V S Cm I K R G R R R R S V Q W C A V S Q P E
HLBD31	A T K Cm F Q W Q R N M R K V R
PXL11	Ac- F Q W Q R N M R K V R K -NH ₂ Ac- G R R R R S
PXL12	Ac- F Q W Q R N M R K V R K -NH ₂ Ac- G R R R R S
PXL13	Ac- F Q W K R A M R K V R E -NH ₂ S R R R R R R -NH ₂
PXL14	Ac- F Q W Q R N M R K V R K P P V S Cm I K R -NH ₂ Ac- G R R R R R S

Cm is acetamidomethyl-cysteine

Table 2

5	peptide	C. albicans		MMC ₉₉ , µg/ml S. aureus		E.coli	
		2 h	24 h	2 h	24 h	2 h	24 h
10	HLBDarg1	6.3	10	12	19	17	3.1
	HLBDarg5	12	12	25	25	25	6
	HLBDarg1optC	12	21	25	25	19	6
15	HLBDarg1optC(K24)	≤50	≤50	16	12	12	6
	HLBD2optCarg1	12	25	25	25	25	12
20	HLBDarg1rak	ND	ND	12	19	12	6
	HLBDarg2	>100	>100	>100	>100	>100	>100
	HLBD31	25	38	100	100	>100	50

25

*ND= not determined

Example 2. Staphylococcus aureus joint infection.

30 Mice. 5 to 8-week old mice were obtained from B&K (Sollentuna, Sweden) and maintained in the animal facility of the Department of Rheumatology, University of Göteborg. They were housed 10 per cage under standard conditions of temperature, and light and fed standard chow and water ad libitum.

35 Bacterial strain and infection. *S. aureus* strain AB-1 was used. The bacteria were injected into the both knee joints (synovial space) of the hind paw. Immediately before injection, bacteria and peptide or vehicle only were mixed. A dose of 2×10^4 *S. aureus* and 100 µg of peptide (HLBDarg1) were injected. The knee of the right hind paw was used as positive control. Also some animals were injected with peptide solution only. The animals were killed at day 3 after infection and the knee joints were fixed in formaline and decalcified for histological evaluation. The number of bacteria present in
40 the left joint was analysed by culturing (cotton swab of joint fluid after removal of skin).

The numbers of *S. aureus* in the joint were higher in the vehicle treated group although no statistical significance was established (Figure 2). The blind scoring of the

joints revealed significant differences between peptide-treated and vehicle treated animals. Thus the peptide appeared to reduce the severity of the Staphylococcus-induced arthritis.

Example 3. Candida albicans skin infection

- 5 Candida albicans. The yeast cells (ATCC64549) were incubated over night in Sabourad broth at 23°C. The cells were washed in phosphate buffer (10 mM, pH 7.4) and adjusted to a concentration of 2×10^{10} /ml.

- Skin infection and peptide treatment. Mice were treated with *C. albicans* on a shaved area (2×10^8 yeast cells per spot) by gentle rubbing a volume of 10 μ l with a blunt plastic rod during anaesthesia. The following day anaesthetized mice were treated with 10 or 20 μ l of a peptide solution or vehicle (phosphate buffer) by applying the volume onto the infected spots. The solution was allowed to dry. After 4 h the treatment was repeated. The day after the animals were killed. Viable counts were performed on washings, obtained from the treated areas by using a metal ring placed over the spot and gentle rubbing in the presence of 100 μ l of phosphate buffer containing Triton-x 100 (0.01%). At most three different concentrations of the peptide were used, starting with 400, 100, and 25 μ g per spot. Although a high variability was obtained (quadruple spots for each concentration), a clear reduction of colony-forming units (CFU) is obtained with the three peptides (Table 3). The results obtained with 400 μ g are presented in Figure 3.

Table 3.

peptide	no. of experiments	CFU (mean \pm SE) treatment	<i>Candida albicans</i>	
			CFU(mean \pm SE) vehicle	p value
HLBDarg1	3	40 \pm 10	166 \pm 33	0.0066
HLBDarg1rak	2	105 \pm 28	414 \pm 60	0.0004
HLBDarg5	1	12 \pm 8.3 ^a	43 \pm 3	0.024

- 30 ^a 1 mg per spot

Example 4. In vitro anti-inflammatory and fibrinolytic effect

- The MeT-5A cell line corresponding to normal human mesothelial cells was maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF; AMS

Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA Laboratories GmbH) and 870 nM human recombinant insulin (Sigma). The cells were induced by addition of recombinant IL-1 (R&D Systems), 0.1 or 0.5 ng/ml in the case of the IL-6 or PAI-1 assay, respectively, into the medium specified above except of
5 containing 5% heat inactivated FBS. The given concentration of peptide HLBD1 Arg rak was added immediately after stimulation by IL-1.

IL-6 production was measured 3 hours after induction by quantitative immunoassay ELISA using human monoclonal anti-IL-6 antibody (R&D Systems).

PAI-1 levels were measured 6 hours after induction by commercially available ELISA
10 kit (Tint-Eliza PAI-1, Trinity Biotech).

The results are expressed in relation to the IL-6 (288 pg/ml) or PAI-1 levels (18.3 ng/ml) obtained without any peptide added.

The results (Figure 4) indicate that IL-6 and PAI-1 production in mesothelial cells is significantly down regulated by the peptide.

15

Example 5. *In vitro* anti-inflammatory effect

The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was maintained in RPMI 1640 (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS; PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES
20 (PAA). The cell density was adjusted to 1×10^6 cells/ml and 500 μ l of the cell suspension was added to 24-well cell culture plates (Sarstedt). The cells were treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to differentiate the monocytes into macrophage-like cells. After 48 hours the cells were stimulated by addition of 0.1 ng/ml LPS (*E. coli* serotype O55:B5; Sigma) into the
25 medium specified above except of containing 5% heat inactivated FBS. The given concentration of peptide HLBD1 Arg rak was added 30 minutes after addition of LPS. The cell supernatants were collected after 6 hours of incubation, centrifuged and analyzed for TNF- α production by ELISA (R&D Systems).

The results (Figure 5) of the experiment demonstrate that TNF- α production in human
30 monocyte derived macrophages is significantly down regulated by the peptide.

Example 6. *In vitro* anti-inflammatory and fibrinolytic effect

The MeT-5A cell line corresponding to normal human mesothelial cells was maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF; AMS Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA Laboratories GmbH) and 870 nM human recombinant insulin (Sigma). The cell density was adjusted to 1.6×10^5 cells/ml and 100 μ l of the cell suspension was added per well to 96-well cell culture plates (Sarstedt). The cells were incubated for 48 hours to allow cells to attach and grow to confluence. After 48 hours the cells were induced by addition of recombinant IL-1 β (R&D Systems), 0.1 or 0.5 ng/ml in the case of the IL-6 or PAI-1 assay, respectively, into the medium specified above except of containing 5% heat inactivated FBS. The given concentrations of the different peptides were added immediately after stimulation by IL-1 β .

The cell supernatants were collected after 3 or 6 hours of incubation and analyzed for IL-6 or PAI-1 by ELISAs specific for IL-6 (R&D Systems) or for PAI-1 (Tint-Eliza PAI-1, Trinity Biotech), respectively.

The results (Figure 6) indicate that IL-6 and PAI-1 production in mesothelial cells is significantly down regulated by the peptides.

Example 7. *In vitro* anti-inflammatory effect

The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was maintained in RPMI 1640 (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS; PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES (PAA). The cell density was adjusted to 1×10^6 cells/ml and 100 μ l of the cell suspension was added per well to 96-well cell culture plates (Sarstedt). The cells were treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to differentiate the monocytes into macrophage-like cells. After 48 hours the cells were stimulated by addition of 0.1 ng/ml LPS (*E. coli* serotype O55:B5; Sigma) into the medium specified above except of containing 5% heat inactivated FBS. The indicated concentrations of the different peptides were added 30 min after addition of LPS. The cell supernatants were collected after 6 hours of incubation, centrifuged and analyzed for TNF- α production by ELISA (R&D Systems).

The results (Figure 7) of the experiment demonstrate that TNF- α production in human monocyte derived macrophages is significantly down regulated by the peptides.

Example 8. Antimicrobial assay

Arg-Arg-Arg-Arg-Arg-Arg- or Arg-Arg-Arg-Arg-Arg- containing peptides (Table 4) have been analysed by an antimicrobial assay using *E.coli*, *S.aureus* and *P. aeruginosa* as test microorganisms.

- 5 Cells were suspended in 1% Brain-heart infusion medium (BHI)(Difco, USA). The concentration of bacterial cells was spectrophotometrically adjusted. Peptides serially diluted in 1% BHI by twofold steps were added in duplicate to the wells of a microtiterplate (100 μ l per well). The bacterial solutions were added in 5 μ l volumes to give a final concentration of approximately 5×10^5 cells per ml. The concentration of
- 10 the stock solution was always checked by viable counts. The microtiterplate was incubated at 37°C for two hours. Five μ l were taken from each well and added as a drop onto a blood agar plate and incubated over night at 37°C.

The concentration of peptide causing a 99% reduction of the inoculum was defined as the MMC_{99} .

15

Table 4

peptide	MMC_{99} , μ g/ml		
	<i>S. aureus</i>	<i>E. coli</i>	<i>P. aeruginosa</i>
PXL11	6.3	1.6	3.1
PXL12	6.3	1.6	3.1
PXL13	6.3	1.6	6.3
PXL15	6.3	1.6	3.1
HLBDarg1rak	6.3	3.1	6.3

CLAIMS

1. A peptide according to formula (I)

R1-Phe-X1-X2-X3-X4-X5-X6-X7-Lys-Val-Arg-X8-R2



wherein amino acid X1 is Gln or Ala, amino acid X2 is Trp or Leu, amino acid X3 is Gln, Ala, Orn, Nle or Lys, amino acid X4 is Arg, Ala or Lys, amino acid X5 is Asn, Ala, Orn or Nle, amino acid X6 is Met, Ala or Leu, amino acid X7 is Arg, Ala or Lys, amino acid X8 is Gly, Lys, Glu or Asp;

10 when X8 is Gly then R3 is Ser-(Arg)_n-X9 and the bond α is a peptide bond between the carboxyl group of Gly and the amino group of Ser;

when X8 is Lys then R3 is X9-(Arg)_n-Ser and the bond α is an amide bond between the ε-amino group in Lys and the carboxyl group in Ser; and

15 when X8 is Glu or Asp then R3 is Ser-(Arg)_n-X9 and the bond α is an amide bond between the γ-carboxyl group of Glu or the β-carboxyl group of Asp and the amino group of Ser;

amino acid X9 is either no amino acid or Gly;

and n is an integer from 1 to 10, preferably an integer from 2 to 6, preferably an integer from 4 to 6, or even more preferably an integer from 3 to 4;

20 R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 3 and N-terminally truncated fragments thereof including

- Gly-Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- 25 Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- 30 Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
- Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,

5
 Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Gln-Pro-Glu-Ala-Thr-Lys-Cys,
 Pro-Glu-Ala-Thr-Lys-Cys,
 Glu-Ala-Thr-Lys-Cys,
 Ala-Thr-Lys-Cys,
 Thr-Lys-Cys,
 and
 Lys-Cys,

R2 is either no amino acid, Pro or a peptide sequence selected from
 10 SEQ ID NO: 4 or C-terminally truncated fragments thereof including
 Pro-Pro-Val-Ser-Cys-Ile-Lys-Arg,
 Pro-Pro-Val-Ser-Cys-Ile-Lys,
 Pro-Pro-Val-Ser-Cys-Ile,
 Pro-Pro-Val-Ser-Cys,
 15 Pro-Pro-Val-Ser,
 Pro-Pro-Val, and
 Pro-Pro;

2. A peptide according to claim 1, wherein amino acid X8 is Gly and R3 is Ser-(Arg)_n-
 X9 and the bond α is a peptide bond between the carboxyl group of Gly and the
 20 amino group of Ser.

3. A peptide according to claim 1, wherein amino acid X8 is Lys and R3 is X9-(Arg)_n-
 Ser and the bond α is an amide bond between the ϵ -amino group in Lys and the
 carboxyl group in Ser.

4. A peptide according to claim 1, wherein amino acid X8 is Glu and R3 is Ser-(Arg)_n-
 25 X9 and the bond α is an amide bond between the γ -carboxyl group in Glu and the
 amino group in Ser.




5. A peptide according to any of claims 1 to 4, wherein amino acid X1 is Gln, amino
 acid X2 is Trp, amino acid X3 is Gln or Lys, amino acid X4 is Arg, amino acid X5 is
 Asn or Ala, amino acid X6 is Met, and amino acid X7 is Arg.

30 6. A peptide according to any of claims 1 to 5, wherein amino acid X9 is Gly.






7. A peptide according to any of claims 1 to 6, wherein R1 is either no amino acid or
 the peptide sequence Ala-Thr-Lys-Cys

8. A peptide according to any of claims 1 to 7, wherein R2 is either no amino acid or the peptide sequence Pro-Pro-Val-Ser-Cys-Ile-Lys-Arg.
9. A peptide according to any of claims 1 to 8, wherein a free COOH at a carboxy terminal end has been transformed into CONH₂.
- 5 10. A peptide according to any of claims 1 to 8, wherein a free NH₂ group at an amino terminal end has been transformed into the amide CH₃CONH.
11. A peptide according to any of claims 1 to 8, wherein the amino acid Cys, if present, has been replaced by an acetamidomethyl-cysteine.
12. A peptide which is selected from
- 10 Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH₂
(SEQ ID NO: 5);
- Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH₂;
15 (SEQ ID NO: 6);
- Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH₂
(SEQ ID NO: 7);
- 20 Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH₂
(SEQ ID NO: 8);
- Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH₂
25 (SEQ ID NO: 9);
- and
- Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH₂
(SEQ ID NO: 10).
- 30 13. A peptide which is selected from
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
|
Gly-Arg-Arg-Arg-Ser

- Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 5 Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 10 Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 15 Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 20 Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 25 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 30 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 35 Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser
- 40 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH₂ ;
 |
 Gly-Arg-Arg-Arg-Arg-Ser



14. A peptide which is selected from



- 5
 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH₂
 |
 Ser-Arg-Arg-Arg-Arg-Gly-NH₂;
- 10
 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-Ile-Lys-Arg;
 |
 Ser-Arg-Arg-Arg-Arg-Gly-NH₂
- 15
 Ala-Thr-Lys-CysM-
 -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH₂
 |
 Ser-Arg-Arg-Arg-Arg-Gly-NH₂;
- 20
 and
 Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH₂
 |
 Ser-Arg-Arg-Arg-Arg-Arg-Arg-Gly-NH₂
- 25
 15. A pharmaceutical composition comprising a peptide according to any of the claims 1 to 14.
16. A pharmaceutical composition according to claim 15 for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
- 30
 17. A pharmaceutical composition according to any one of the claims 15 to 16 formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.
18. Food stuff comprising a peptide according to any of the claims 1 to 14.
- 35
 19. Use of a peptide according to any one of the claims 1 to 14 for the production of a medicinal product for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
20. Use according to claim 19, wherein the medicinal product is formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.

21. A method for treatment or prevention of infections, inflammations, tumours, pain, wounds and scars wherein an effective amount of a peptide according to any of claims 1 to 14, fragments, and functionally equivalent homologues and analogues thereof, is administered to a patient.
- 5 22. A method according to claim 21, wherein the substance is orally, systemically, parenterally, locally or topically administered.
23. A method according to claim 22, wherein the substance is included in a food stuff.
24. A method according to claim 23, wherein the substance is included in an infant formula food.
- 10 25. A peptide according to any one of the claims 1 to 14 for use as a medicament.
26. A peptide according to any one of the claims 1 to 14 for the treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
27. A peptide according to claim 26, formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.

Figure 1





Figure 3**C. albicans**

Figure 4






Figure 5

Figure 6






Figure 7



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2008/065186

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K14/79 A61K38/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, Sequence Search

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ODELL E W ET AL: "ANTIBACTERIAL ACTIVITY OF PEPTIDES HOMOLOGOUS TO A LOOP REGION IN HUMAN LACTOFERRIN" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 382, 1996, pages 175-178, XP002921040 ISSN: 0014-5793 abstract; table 1</p> <p align="center">----- -/--</p>	1-27

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 March 2009

Date of mailing of the international search report

20/03/2009

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040.
Fax: (+31-70) 340-3016

Authorized officer

Krüger, Julia

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2008/065186

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BERKEL VAN P H C ET AL: "N-TERMINAL STRETCH ARG2, ARG3, ARG4 AND ARG5 OF HUMAN LACTOFERRIN IS ESSENTIAL FOR BINDING TO HEPARIN, BACTERIAL LIPOPOLYSACCHARIDE, HUMAN LYSOZYME AND DNA" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 328, 15 November 1997 (1997-11-15), pages 145-151, XP002072084 ISSN: 0264-6021 the whole document	1-27
A	AZUMA M ET AL: "Antibacterial activity of multiple antigen peptides homologous to a loop region in human lactoferrin" JOURNAL OF PEPTIDE RESEARCH, vol. 54, no. 3, September 1999 (1999-09), pages 237-241, XP002475047 ISSN: 1397-002X abstract; figure 1	1-27
A	MORIARTY L C ET AL: "Factors contributing to the potency of antimicrobial cationic peptides from the N-terminal region of human lactoferrin" FEMS MICROBIOLOGY LETTERS, AMSTERDAM, NL, vol. 239, no. 2, 15 October 2004 (2004-10-15); pages 295-299, XP004597837 ISSN: 0378-1097 the whole document	1-27
A	WO 01/34641 A (PHARMING INTELLECTUAL PTY BV [NL]; BERKEL PATRICK HENDRIKUS CORNE [NL]) 17 May 2001 (2001-05-17) page 8, line 29 - page 9, line 26; example 1	1-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2008/065186

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0134641	A	17-05-2001	AT 313562 T 15-01-2006
			AU 776044 B2 26-08-2004
			AU 1901501 A 06-06-2001
			CA 2388910 A1 17-05-2001
			DE 60025026 T2 03-08-2006
			DK 1228097 T3 18-04-2006
			EP 1228097 A2 07-08-2002
			ES 2256070 T3 16-07-2006
			JP 2003521483 T 15-07-2003
			PT 1228097 T 31-05-2006
